A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms

Journal of Lipid Research

Volumn 58, Issue 9, 2017, Pages 1834-1844

  Mack, Salome ^a   Coassin, Stefan ^b   Rueedi, Rico ^c   Yousri, Noha A ^d   Seppälä, Ilkka ^f   Gieger, Christian ^f,u   Schönherr, Sebastian ^e,w   Forer, Lukas ^f,t   Erhart, Gertraud ^h,v   Marques Vidal, Pedro ⁱ   Ried, Janina S ^a   Waeber, Gerard ^g,i,s   Bergmann, Sven ^j   Dähnhardt, Doreen ^k   Stöckl, Andrea ^k,l   Raitakari, Olli T ^m   Kähönen, Mika ^n,x   Peters, Annette ^o   Meitinger, Thomas ^a,g   Strauch, Konstantin ^k   Kedenko, Ludmilla ^p,y   Paulweber, Bernhard ^q   Lehtimäki, Terho ^d,r   Hunt, Steven C ^b   Vollenweider, Peter ^r   Lamina, Claudia ^a   Kronenberg, Florian ^a   more..

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^e Alexandria University The Faculty Of Engineering   (Egypt)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g Institute of Epidemiology II   (Germany)

^h Unit of Molecular Epidemiology   (Germany)

ⁱ Institute of Human Genetics   (Germany)

^j INSTITUTE OF EPIDEMIOLOGY   (Germany)

^k Department of Medicine ^*  (Finland)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m TURKU UNIVERSITY HOSPITAL   (Finland)

ⁿ Research Centre of Applied and Preventive Cardiovascular Medicine   (Finland)

^o UNIVERSITY OF TURKU   (Finland)

^p TAMPERE UNIVERSITY HOSPITAL   (Finland)

^q DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^r GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^s TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^t Technische Universität München ^*  (Germany)

^u Institute of Medical Informatics Biometry and Epidemiology   (Germany)

^v UNIVERSITY OF MUNICH   (Germany)

^w First Department of Internal Medicine   (United States)

^x PARACELSUS MEDICAL UNIVERSITY   (Austria)

^y UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN A; APOLIPOPROTEIN A; ISOPROTEIN;

APOE GENE; ARTICLE; CARDIOVASCULAR RISK; CHROMOSOME 19; CHROMOSOME 6; CORONARY ARTERY DISEASE; ETHNICITY; EXON; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HERITABILITY; HUMAN; LPA GENE; MALE; NULL ALLELE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TLR2 GENE; ANIMAL; GENETICS; META ANALYSIS; METABOLISM; PROCEDURES; SEXUAL CHARACTERISTICS;

ANIMALS; APOLIPOPROTEINS A; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPOPROTEIN(A); POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; SEX CHARACTERISTICS;

EID: 85029424122     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M076232     Document Type: Article

References (63)

1. Schmidt, K., A. Noureen, F. Kronenberg, and G. Utermann. 2016. Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57: 1339-1359.
2. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90: 52-60.
3. Kronenberg, F., and G. Utermann. 2013. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273: 6-30.
4. Kraft, H. G., S. Köchl, H. J. Menzel, C. Sandholzer, and G. Utermann. 1992. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum. Genet. 90: 220-230.
5. Lackner, C., E. Boerwinkle, C. C. Leffert, T. Rahmig, and H. H. Hobbs. 1991. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-feld gel electrophoresis. J. Clin. Invest. 87: 2153-2161.
6. Kraft, H. G., A. Lingenhel, R. W. Pang, R. Delport, M. Trommsdorff, H. Vermaak, E. D. Janus, and G. Utermann. 1996. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur. J. Hum. Genet. 4: 74-87.
7. Melzer, D., J. R. B. Perry, D. Hernandez, A-M. Corsi, K. Stevens, I. Rafferty, F. Lauretani, A. Murray, J. R. Gibbs, G. Paolisso, et al. 2008. A genome-wide association study identifes protein quantitative trait loci (pQTLs). PLoS Genet. 4: e1000072.
8. Ober, C., A. S. Nord, E. E. Thompson, L. Pan, Z. Tan, D. Cusanovich, Y. Sun, R. Nicolae, C. Edelstein, D. H. Schneider, et al. 2009. Genome-wide association study of plasma lipoprotein(a) levels identifes multiple genes on chromosome 6q. J. Lipid Res. 50: 798-806.
9. Zabaneh, D., M. Kumari, M. Sandhu, N. Wareham, N. Wainwright, T. Papamarkou, J. Hopewell, R. Clarke, K. Li, J. Palmen, et al. 2011. Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14, 500 participants of six White European cohorts. Atherosclerosis. 217: 447-451.
10. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al.; PROCARDIS Consortium. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
11. Qi, Q., T. Workalemahu, C. Zhang, F. B. Hu, and L. Qi. 2012. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur. Heart J. 33: 325-334.
12. Kivimäki, M., C. G. Magnussen, M. Juonala, M. Kähönen, J. Kettunen, B-M. Loo, T. Lehtimäki, J. Viikari, and O. T. Raitakari. 2011. Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study. Int. J. Epidemiol. 40: 470-478.
13. Lu, W., Y-C. Cheng, K. Chen, H. Wang, G. S. Gerhard, C. D. Still, X. Chu, R. Yang, A. Parihar, J. R. O'Connell, et al. 2015. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum. Mol. Genet. 24: 2390-2400.
14. Li, J., L. A. Lange, J. Sabourin, Q. Duan, W. Valdar, M. S. Willis, Y. Li, J. G. Wilson, and E. M. Lange. 2015. Genome-and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. J. Hum. Genet. 60: 755-761.
15. Moriarty, P. M., S. A. Varvel, P. L. S. M. Gordts, J. P. McConnell, and S. Tsimikas. 2017. Lipoprotein(a) mass levels increase signif-cantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler. Thromb. Vasc. Biol. 37: 580-588.
16. Utermann, G., H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz. 1987. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80: 458-465.
17. Han, B., and E. Eskin. 2011. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet. 88: 586-598.
18. Behrens, G., T. W. Winkler, M. Gorski, M. F. Leitzmann, and I. M. Heid. 2011. To stratify or not to stratify: power considerations for population-based genome-wide association studies of quantitative traits. Genet. Epidemiol. 35: 867-879.
19. Arnold, M., J. Raffer, A. Pfeufer, K. Suhre, and G. Kastenmüller. 2015. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics. 31: 1334-1336.
20. Yang, J., S. H. Lee, M. E. Goddard, and P. M. Visscher. 2011. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88: 76-82.
21. Li, M-X., P. C. Sham, S. S. Cherny, and Y-Q. Song. 2010. A knowledge-based weighting framework to boost the power of genome-wide association studies. PLoS One. 5: e14480.
22. Li, M-X., H-S. Gui, J. S. H. Kwan, and P. C. Sham. 2011. GATES: a rapid and powerful gene-based association test using extended Simes procedure. Am. J. Hum. Genet. 88: 283-293.
23. Nikpay, M., A. Goel, H-H. Won, L. M. Hall, C. Willenborg, S. Kanoni, D. Saleheen, T. Kyriakou, C. P. Nelson, J. C. Hopewell, et al. 2015. A comprehensive 1, 000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 47: 1121-1130.
24. de Los Campos, G., D. Sorensen, and D. Gianola. 2015. Genomic heritability: what is it? PLoS Genet. 11: e1005048.
25. Birney, E., J. A. Stamatoyannopoulos, A. Dutta, R. Guigó, T. R. Gingeras, E. H. Margulies, Z. Weng, M. Snyder, E. T. Dermitzakis, R. E. Thurman, et al. 2007. Identifcation and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447: 799-816.
26. Lesurf, R., K. C. Cotto, G. Wang, M. Griffth, K. Kasaian, S. J. M. Jones, S. B. Montgomery, and O. L. Griffth; Open Regulatory Annotation Consortium. 2016. ORegAnno 3.0: a community-driven resource for curated regulatory annotation. Nucleic Acids Res. 44: D126-D132.
27. GTEx Consortium. 2015. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 348: 648-660.
28. Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky, A. Gerasimova, P. Bork, A. S. Kondrashov, and S. R. Sunyaev. 2010. A method and server for predicting damaging missense mutations. Nat. Methods. 7: 248-249.
29. Kumar, P., S. Henikoff, and P. C. Ng. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4: 1073-1081.
30. Ogorelkova, M., H. G. Kraft, C. Ehnholm, and G. Utermann. 2001. Single nucleotide polymorphisms in exons of the apo(a) kringle IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum. Mol. Genet. 10: 815-824.
31. Kyriakou, T., U. Seedorf, A. Goel, J. C. Hopewell, R. Clarke, H. Watkins, and M. Farrall; PROCARDIS Consortium. 2014. A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk. Arterioscler. Thromb. Vasc. Biol. 34: 2095-2099.
32. Lim, E. T., P. Würtz, A. S. Havulinna, P. Palta, T. Tukiainen, K. Rehnström, T. Esko, R. Mägi, M. Inouye, T. Lappalainen, et al. 2014. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 10: e1004494.
33. Parson, W., H. G. Kraft, H. Niederstätter, A. W. Lingenhel, S. Köchl, F. Fresser, and G. Utermann. 2004. A common nonsense mutation in the repetitive kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). Hum. Mutat. 24: 474-480.
34. Noureen, A., F. Fresser, G. Utermann, and K. Schmidt. 2015. Sequence variation within the KIV-2 copy number polymorphism of the human LPA gene in African, Asian, and European populations. PLoS One. 10: e0121582.
35. Kronenberg, F. 2014. Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better. J. Intern. Med. 276: 243-247.
36. Arai, K., M. M. Luke, M. L. Koschinsky, E. R. Miller, C. R. Pullinger, J. L. Witztum, J. P. Kane, and S. Tsimikas. 2010. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phos-pholipids on apolipoprotein B-100 particles. Atherosclerosis. 209: 498-503.
37. Lee, S-R., A. Prasad, Y-S. Choi, C. Xing, P. Clopton, J. L. Witztum, and S. Tsimikas. 2017. LPA gene, ethnicity, and cardiovascular events. Circulation. 135: 251-263.
38. Ogorelkova, M., A. Gruber, and G. Utermann. 1999. Molecular basis of congenital lp(a) defciency: a frequent apo(a) "null" mutation in Caucasians. Hum. Mol. Genet. 8: 2087-2096.
39. Surakka, I., M. Horikoshi, R. Mägi, A-P. Sarin, A. Mahajan, V. Lagou, L. Marullo, T. Ferreira, B. Miraglio, S. Timonen, et al. 2015. The impact of low-frequency and rare variants on lipid levels. Nat. Genet. 47: 589-597.
40. van Leeuwen, E. M., A. Sabo, J. C. Bis, J. E. Huffman, A. Manichaikul, A. V Smith, M. F. Feitosa, S. Demissie, P. K. Joshi, Q. Duan, et al. 2016. Meta-analysis of 49, 549 individuals imputed with the 1000 Genomes Project reveals an exonic damaging variant in ANGPTL4 determining fasting TG levels. J. Med. Genet. 53: 441-449.
41. Kinpara, K., H. Okada, A. Yoneyama, M. Okubo, and T. Murase. 2011. Lipoprotein(a)-cholesterol: a signifcant component of serum cholesterol. Clin. Chim. Acta. 412: 1783-1787.
42. Wade, D. P., L. H. Puckey, B. L. Knight, F. Acquati, A. Mihalich, and R. Taramelli. 1997. Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. J. Biol. Chem. 272: 30387-30399.
43. Puckey, L. H., and B. L. Knight. 2003. Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene. Atherosclerosis. 166: 119-127.
44. Crawford, D. C., Z. Peng, J-F. Cheng, D. Boffelli, M. Ahearn, D. Nguyen, T. Shaffer, Q. Yi, R. J. Livingston, M. J. Rieder, et al. 2008. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. Hum. Hered. 66: 199-209.
45. Lanktree, M. B., S. S. Anand, S. Yusuf, and R. A. Hegele; SHARE Investigators. 2010. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ. Cardiovasc. Genet. 3: 39-46.
46. Prins, J., F. R. Leus, B. N. Bouma, and H. J. van Rijn. 1999. The identifcation of polymorphisms in the coding region of the apoli-poprotein (a) gene-association with earlier identifed polymorphic sites and infuence on the lipoprotein (a) concentration. Thromb. Haemost. 82: 1709-1717.
47. Coassin, S., G. Erhart, H. Weissensteiner, M. Eca Guimarães de Araújo, C. Lamina, S. Schönherr, L. Forer, M. Haun, J. L. Losso, A. Köttgen, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur. Heart J. Epub ahead of print. April 25, 2017; doi:.
48. Chow, C. K., S. Islam, L. Bautista, Z. Rumboldt, A. Yusufali, C. Xie, S. S. Anand, J. C. Engert, S. Rangarajan, and S. Yusuf. 2011. Parental history and myocardial infarction risk across the world: the INTERHEART Study. J. Am. Coll. Cardiol. 57: 619-627.
49. Yoshino, S., R. Cilluffo, M. Prasad, P. J. M. Best, E. J. Atkinson, T. Aoki, J. M. Cunningham, M. de Andrade, L. O. Lerman, and A. Lerman. 2016. Sex-specifc genetic variants are associated with coronary endothelial dysfunction. J. Am. Heart Assoc. 5: e002544.
50. Solomon, T., E. N. Smith, H. Matsui, S. K. Braekkan, INVENT Consortium, T. Wilsgaard, I. Njølstad, E. B. Mathiesen, J-B. Hansen, and K. A. Frazer. 2016. Associations between common and rare ex-onic genetic variants and serum levels of 20 cardiovascular-related proteins: the Tromsø Study. Circ. Cardiovasc. Genet. 9: 375-383.
51. Phillips, M. C. 2014. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 66: 616-623.
52. Scanu, A. M., D. Pfaffnger, and C. Edelstein. 1994. Post-prandial Lp(a): identifcation of a triglyceride-rich particle containing apo E. Chem. Phys. Lipids. 67-68: 193-198.
53. Hopkins, P. N., E. A. Brinton, and M. N. Nanjee. 2014. Hyperli-poproteinemia type 3: the forgotten phenotype. Curr. Atheroscler. Rep. 16: 440.
54. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 269: 604-607.
55. Lindahl, G., F. Mailly, S. Humphries, and M. Seed. 1994. Apolipoprotein E phenotype and lipoprotein(a) in familial hyper-cholesterolaemia: implication for lipoprotein(a) metabolism. Clin. Investig. 72: 631-638.
56. Rader, D. J., W. Cain, L. A. Zech, D. Usher, and H. B. Brewer. 1993. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J. Clin. Invest. 91: 443-447.
57. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic re-ticulum stress. Cell Metab. 12: 467-482.
58. Liu, Y., H. Yin, M. Zhao, and Q. Lu. 2014. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 47: 136-147.
59. Feingold, K. R., A. H. Moser, J. K. Shigenaga, S. M. Patzek, and C. Grunfeld. 2008. Infammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun. 374: 341-344.
60. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 301: 2331-2339.
61. Emdin, C. A., A. V. Khera, P. Natarajan, D. Klarin, H-H. Won, G. M. Peloso, N. O. Stitziel, A. Nomura, S. M. Zekavat, A. G. Bick, et al; CHARGE-Heart Failure Consortium and CARDIoGRAM Exome Consortium. 2016. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J. Am. Coll. Cardiol. 68: 2761-2772.
62. Navarese, E. P., M. Kolodziejczak, V. Schulze, P. A. Gurbel, U. Tantry, Y. Lin, M. Brockmeyer, D. E. Kandzari, J. M. Kubica, R. B. D'Agostino, et al. 2015. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann. Intern. Med. 163: 40-51.
63. Viney, N. J., J. C. van Capelleveen, R. S. Geary, S. Xia, J. A. Tami, R. Z. Yu, S. M. Marcovina, S. G. Hughes, M. J. Graham, R. M. Crooke, et al. 2016. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 388: 2239-2253.